Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Gemigliptin/Rosuvastatin and Ezetimibe in Healthy Volunteers
NCT02947139Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Sep 2016
- Primary completion
- Oct 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gemigliptin, rosuvastatin and ezetimibe in type 2 diabetes mellitus (T2DM) and hypercholesterolemia (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Peak Plasma Concentration and Area under the plasma concentration versus time curve. Started Sep 2016; status: completed.
02
Drugs
gemigliptinrosuvastatinezetimibe
03
Conditions
type 2 diabetes mellitus (T2DM)hypercholesterolemia
Beyond the preview
Go deeper on NCT02947139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947139.